LivPure: A Structured Review
- Form
- capsule
- Price range
- $50–70 per bottle (1-month supply); $39–50 per bottle in 6-bottle bundles
- Made in
- United States
- Marketed for
- Marketed as a dietary supplement intended to support liver health and metabolic function.
- Main point of attention
- Berberine dose (100 mg) is substantially below the dose range used in clinical trials for metabolic outcomes (typically 900–1,500 mg/day).
Composition
| Ingredient | Dose in this product | Typical studied dose | Match |
|---|---|---|---|
| Silymarin | 100 mg | 140–800 mg/day | Low |
| Berberine | 100 mg | 900–1500 mg/day | Low |
| Molybdenum | 35 mcg | 0.045–2 mg/day | Low |
Mediterranean Super-Blend — (individual ingredient doses not disclosed)
Indication of use
Marketed as a dietary supplement intended to support liver health and metabolic function. The label positions the product for adults seeking metabolic support, with general references to hepatic support and weight management. Specific marketing claims have not been independently verified.
Ingredient evidence
Evidence base is mixed. Some clinical trials in chronic liver disease (viral hepatitis, alcoholic liver disease, NAFLD) show modest improvements in liver enzymes; others are negative or inconclusive. Quality of older studies is variable.
View key studies
-
Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. JAMA. 2012;308(3):274-82.
PMID: 22797644
Multicenter RCT in 154 patients with chronic HCV non-responsive to interferon. Silymarin at higher doses did NOT significantly reduce ALT levels vs placebo.
-
Cacciapuoti F, Scognamiglio A, Palumbo R, et al. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013;5(3):109-13.
PMID: 23556043
Small trial suggesting improvement in liver enzymes and ultrasound findings in NAFLD patients.
Multiple randomized controlled trials and meta-analyses support efficacy for glycemic control in type 2 diabetes and metabolic syndrome at doses around 1,500 mg/day. Effects on HbA1c are comparable to first-line oral hypoglycemics in some studies.
View key studies
-
Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-7.
PMID: 18442638
RCT comparing berberine 500mg TID to metformin 500mg TID in 36 newly diagnosed T2D patients. HbA1c reduction was comparable between groups (~2% absolute reduction).
-
Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81.
PMID: 25498346
Meta-analysis of 27 RCTs (2,569 participants). Berberine showed significant reduction in fasting blood glucose, HbA1c, total cholesterol, and triglycerides.
Established essential micronutrient with a defined Recommended Dietary Allowance (RDA) of 45 mcg/day for adults in the United States. Deficiency is extremely rare in well-fed populations. Supplementation beyond RDA in healthy individuals has not been shown to provide additional benefits.
View key studies
-
Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington (DC): National Academies Press; 2001.
PMID: 25057538
Foundational reference establishing molybdenum RDA and tolerable upper intake levels.
Components of the Mediterranean Super-Blend are not individually disclosed and therefore not evaluated.
Safety profile
The product label does not list specific contraindications beyond general advice to consult a healthcare provider before use. Published literature on the active ingredients reports gastrointestinal effects as the most common adverse events at studied doses. Berberine has documented interactions with cytochrome P450 enzymes that may affect metabolism of various medications. Population considerations reported in the literature include pregnancy, lactation, hepatic impairment, and concurrent use of antidiabetic or anticoagulant medications.
Factual observations
- Discloses individual doses for three active ingredients (silymarin, berberine, molybdenum).
- Manufactured in an FDA-registered, cGMP-compliant facility.
- Includes silymarin, which has consistent evidence base for hepatic support at the studied dose range.
- Berberine dose (100 mg) is substantially below the dose range used in clinical trials for metabolic outcomes (typically 900–1,500 mg/day).
- Uses a proprietary 'Mediterranean Super-Blend' without disclosing individual ingredient quantities, which prevents independent assessment of those components.
- Marketing emphasizes weight-loss outcomes that exceed what the ingredient evidence at these specific doses would directly support.
Availability info pending.
Pricing and availability are set by the manufacturer and may change after the last review date. NaturaPeak does not sell this product directly. Any purchase link shown may be an affiliate link, as described below.